Skip to main content

Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”

The Original Article was published on 17 June 2022

A Letter to the Editor to this article was published on 17 June 2022

This is a preview of subscription content, access via your institution.


  1. Sendi P, Schwenkglenks M. Risk-adjusted performance measures: a comment on Elbasha. Pharmacoeconomics. 2022;20:20.

    Google Scholar 

  2. Elbasha EH. Cost-effectiveness risk-aversion curves: comparison of risk-adjusted performance measures and expected-utility approaches. Pharmacoeconomics. 2022;40:497–507.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sendi P. Dealing with bad risk in cost-effectiveness analysis: the cost-effectiveness risk-aversion curve. Pharmacoeconomics. 2021;39:161–9.

    Article  Google Scholar 

  4. Sendi P, Matter-Walstra K, Schwenkglenks M. Handling uncertainty in cost-effectiveness analysis: budget impact and risk aversion. Healthcare. 2021;9:1419.

    Article  Google Scholar 

Download references


This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Merck Sharp and Dohme.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Elamin H. Elbasha.

Ethics declarations

Conflicts of interest

The author declares that he has no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Elbasha, E.H. Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”. PharmacoEconomics 40, 741–742 (2022).

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: